Algernon Pharmaceuticals Inc (AGN) NPV A

Algernon Pharmaceuticals Inc. is a Canadian clinical-stage pharmaceutical development company investigating multiple drugs for unmet global medical needs. The Company is also the parent company of a private subsidiary, Algernon NeuroScience Inc., that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic N,N-Dimethyltryptamine (DMT) for stroke and traumatic brain injury. It is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD). The Company operates through two segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. Its pipeline includes NP-251 (Repirinast) and DMT (AP-188). Its lead candidate, Repirinast, is being developed as a potential treatment for kidney inflammation and fibrosis.